Solabia announces the acquisition of the Botanical Actives and In-Vitro Diagnostics (“IVD”) activity of SEQENS, which develops and manufactures high performance vegetal active ingredients for cosmetics, as well as plasma and serum solutions for diagnostics applications. 

The business operates a facility in Limoges (France), recognized for its advanced botanical extraction and high-end manufacturing capabilities. Its ingredients and diagnostic solutions are commercialized worldwide and used by leading brands across both sectors. 

This acquisition represents a strategic opportunity for Solabia to reinforce its global position as a leading supplier of high performance substantiated botanical active ingredients for cosmetics applications, while also securing a critical raw material supply for its diagnostics activities. By combining forces, the Group will accelerate the development of innovative solutions across both the cosmetics and diagnostics markets, two sectors in which Solabia is already strongly active and committed to long-term growth. 

Jean-Baptiste Dellon, CEO of Solabia, commented: 

“We are pleased to welcome the SEQENS Botanical Actives and IVD teams into Solabia. Because we operate in the same core activities, this acquisition is a natural and highly complementary fit. By combining our capabilities, we will reinforce our market position, secure critical supply chains, and offer our clients more robust and innovative solutions. This acquisition fully supports our development strategy as we continue to strengthen our business in markets with strong growth potential.” 

Pascal Villemagne, CEO of SEQENS, declared: 

“This transaction is fully consistent with our long-term strategic vision. It enables SEQENS to further focus on its core priorities, while ensuring that the Limoges teams join a group whose industrial culture, scientific expertise and growth ambitions are strongly aligned with their activities. We are confident that this new chapter with Solabia offers a robust and sustainable platform for the continued development of the site, its people and its know-how.” 

About Solabia 

Solabia is a vertically integrated manufacturer of natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, biotechnology and microbiology industries. Solabia is also a producer of culture media, supplements and detection kits for food testing, pharmaceutical industry and microbiology laboratories. With eleven production facilities and multiple R&D centers, Solabia is a major player in the global cosmetics, nutraceutical and pharmaceutical ingredient markets with presence in North and South America, Europe, Asia, Middle East and Africa. 

More information can be found at: https://www.solabia.com/en

About SEQENS 

SEQENS is a world leader in the development and production of active pharmaceutical ingredients, intermediates and specialty ingredients, with 15 production sites, 5 R&D centers and 2,700 employees on 3 continents. 

As an integrated player across the entire value chain - from raw materials to active ingredients and from R&D to industrialization - SEQENS offers a broad portfolio of active pharmaceutical ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop and implement the best available technologies. 

More information can be found at: https://www.seqens.com/